Abstract
Abrocitinib, an oral small-molecule Janus kinase 1 (JAK1) inhibitor, is used for the treatment of -moderate-to-severe atopic dermatitis (AD). However, due to safety concerns, further clinical experience is warranted, especially for elderly patients with AD. The aim of this study was to assess the rapidity, effectiveness, and safety of short-term abrocitinib in combination with medicated topical therapy for managing -moderate-to-severe AD in elderly patients. A total of 57 elderly patients (≥65 years old) with moderate-to-severe AD who received oral abrocitinib at a dose of 100 mg/day, combined with topical medicated therapy for a minimum of 2 weeks, were included in the analysis. Results indicated that 91.23% of patients achieved the PP-NRS response at Week 2, and itching remained well controlled at Week 12. Additionally, 47.37% of patients achieved EASI-50, and 14.04% reached EASI-75 by Week 2. Notably, none of the 57 patients experienced any adverse events during the 12-week follow-up period. A shorter duration of AD was associated with better efficacy. Short-term abrocitinib in combination with medicated topical therapy may represent a new treatment approach in clinical practice for elderly AD patients, offering a rapid-onset and convenient treatment option to alleviate itching, achieve treatment goals, and manage medication risks simultaneously.